Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...

"The collaboration with Tempus will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...

July 9 (Reuters) - Wall Street brokerages started covering SoftBank Group-backed Tempus AI (TEM.O), opens new tab on a bullish note on Tuesday, betting that the company's AI-powered library of ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher by 7.45% to $35.82 during Tuesday’s session after the company announced it was granted Advanced Diagnostic Laboratory Test (ADLT) status for its ...

Tempus AI has expanded its relationship with Personalis, investing $36 million in the oncology biotech and becoming the exclusive commercial partner for its test to detect minimal residual disease, or ...

Tempus AI TEM continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay ...

Tempus AI stock is showing a mixed technical picture, with a moderately bearish trend and ongoing selling pressure, indicating potential downside risk. The stock, at $69.85, sits well below its ...

Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care ...